Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, Oppenheimer J, Papi A, Pascoe S, Brusselle G, Peachey G, Sule N, Tabberer M, Pavord ID. Lee LA, et al. Among authors: tabberer m. Lancet Respir Med. 2021 Jan;9(1):69-84. doi: 10.1016/S2213-2600(20)30389-1. Epub 2020 Sep 9. Lancet Respir Med. 2021. PMID: 32918892 Clinical Trial.
Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A. Decramer M, et al. Among authors: tabberer m. Lancet Respir Med. 2014 Jun;2(6):472-86. doi: 10.1016/S2213-2600(14)70065-7. Epub 2014 May 14. Lancet Respir Med. 2014. PMID: 24835833 Clinical Trial.
Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in patients with asthma.
Chan R, Sousa AR, Mallett S, Hynds P, Homayoun-Valiani F, Tabberer M, Mehta R. Chan R, et al. Among authors: tabberer m. Pulm Pharmacol Ther. 2016 Dec;41:19-24. doi: 10.1016/j.pupt.2016.09.002. Epub 2016 Sep 4. Pulm Pharmacol Ther. 2016. PMID: 27599598 Clinical Trial.
Interpreting patient-reported outcomes from clinical trials in COPD: a discussion.
Jones PW, Rennard S, Tabberer M, Riley JH, Vahdati-Bolouri M, Barnes NC. Jones PW, et al. Among authors: tabberer m. Int J Chron Obstruct Pulmon Dis. 2016 Dec 7;11:3069-3078. doi: 10.2147/COPD.S117378. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27994447 Free PMC article. Review.
Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler versus a multi-dose inhaler in patients with chronic obstructive pulmonary disease.
Chan R, Sousa AR, Hynds P, Homayoun-Valiani F, Edwards D, Tabberer M. Chan R, et al. Among authors: tabberer m. Pulm Pharmacol Ther. 2017 Apr;43:12-19. doi: 10.1016/j.pupt.2017.01.009. Epub 2017 Jan 21. Pulm Pharmacol Ther. 2017. PMID: 28115223 Clinical Trial.
Reply: "FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease" and "Triple Therapy in Chronic Obstructive Pulmonary Disease".
Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ. Lipson DA, et al. Among authors: tabberer m. Am J Respir Crit Care Med. 2017 Oct 15;196(8):1083-1084. doi: 10.1164/rccm.201704-0818LE. Am J Respir Crit Care Med. 2017. PMID: 28534669 No abstract available.
67 results